Trial
NCT02243787
Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Covagen
Collaborators
—
Condition
Plaque Psoriasis
Intervention
COVA322
Why stopped
Based on the observed safety profile of COVA322, the sponsor decided to stop the clinical study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-01